Phytopharm plc Stock London S.E.
Stocks
GB0006869720
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 07-13 | Oil rises as Iran escalation keeps FTSE subdued | AN |
| 07-13 | Ixico notes ending of Huntington's disease programmes | AN |
| Market Cap | 16.97M 22.45M 20.02M 18.67M 31.94M 2.17B 32.26M 224M 87.01M 1.11B 84.2M 82.46M 3.54B | P/E 2026 * |
-5.54x | P/E 2027 * | -5.96x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77M 8.96M 7.99M 7.45M 12.74M 867M 12.87M 89.3M 34.71M 442M 33.59M 32.9M 1.41B | EV / Sales 2026 * |
0.85x | EV / Sales 2027 * | 1.21x |
| Free-Float |
89.57% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Phytopharm plc
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 2024-08-18 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 2019-08-20 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 2019-08-20 |
Katherine Rogers
BRD | Director/Board Member | 60 | 2022-01-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.19% | -3.19% | +44.60% | +87.98% | 74.68B | |
| -15.86% | -16.67% | +3.92% | +50.90% | 58.7B | |
| -2.39% | -2.05% | +4.29% | +31.33% | 48.36B | |
| -6.35% | -8.35% | +303.95% | +651.28% | 43.05B | |
| +0.30% | -3.71% | +28.89% | +30.33% | 42.48B | |
| -3.82% | -4.32% | +2.49% | +101.36% | 41.39B | |
| -2.13% | +1.07% | +7.51% | +50.31% | 31.29B | |
| -3.35% | -6.35% | -13.20% | -17.22% | 23.93B | |
| -1.24% | -11.97% | -38.10% | +311.13% | 22.22B | |
| Average | -4.23% | -2.63% | +38.26% | +144.16% | 42.9B | |
| Weighted average by Cap. | -4.86% | -1.88% | +44.70% | +136.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8M 10.59M 9.44M 8.8M 15.05M 1.02B 15.21M 106M 41.02M 522M 39.69M 38.87M 1.67B | 9M 11.91M 10.62M 9.9M 16.94M 1.15B 17.11M 119M 46.14M 587M 44.65M 43.73M 1.88B |
| Net income | -2.14M -2.84M -2.53M -2.36M -4.03M -274M -4.07M -28.26M -10.99M -140M -10.63M -10.41M -448M | -2.8M -3.71M -3.3M -3.08M -5.27M -359M -5.32M -36.94M -14.36M -183M -13.9M -13.61M -585M |
| Net Debt | -10.2M -13.5M -12.03M -11.22M -19.19M -1.31B -19.39M -135M -52.29M -666M -50.61M -49.56M -2.13B | -6.1M -8.07M -7.19M -6.71M -11.48M -781M -11.6M -80.45M -31.27M -398M -30.26M -29.64M -1.27B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
